Literature DB >> 6271048

Activity of moxalactam and cefotaxime alone and in combination with ampicillin or penicillin against group B streptococci.

S H Landesman, M L Corrado, C E Cherubin, M F Sierra.   

Abstract

The activities of moxalactam and cefotaxime, alone and combined with ampicillin or penicillin, against 40 isolates of group B streptococci were assessed by using the microtiter broth dilution, checkerboard, and time-kill techniques. Penicillin and cefotaxime were bactericidal for all isolates at concentrations of 0.06 micrograms/ml or less. Ampicillin was slightly less active. Moxalactam was bactericidal for all strains at concentrations of 4 to 8 micrograms/ml. The ampicillin- moxalactam combination was partially synergistic for 60% of the isolates tested; the ampicillin-cefotaxime combination was partially synergistic for 35% of these isolates. No instances of antagonism were observed. In time-kill evaluations, ampicillin (3.0 micrograms/ml) and penicillin (0.75 micrograms/ml) effected 2.5 to 3.5 log10 reductions in numbers of colony-forming units. The addition of 4 micrograms of cefotaxime per ml or 8 to 16 micrograms of moxalactam per ml to penicillin or ampicillin did not alter killing kinetics. Moxalactam and cefotaxime neither enhanced nor decreased the activity of ampicillin or penicillin against group B streptococci.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271048      PMCID: PMC181524          DOI: 10.1128/AAC.19.5.794

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  PURULENT MENINGITIS IN THE NEONATAL PERIOD.

Authors:  J S YU; A GRAUAUG
Journal:  Arch Dis Child       Date:  1963-08       Impact factor: 3.791

2.  A pharmacologic evaluation of penicillin in children with purulent meningitis.

Authors:  J P Hieber; J D Nelson
Journal:  N Engl J Med       Date:  1977-08-25       Impact factor: 91.245

3.  Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin.

Authors:  V T Andriole
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

4.  Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants.

Authors:  C J Baker; F F Barrett; R C Gordon; M D Yow
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

5.  Ampicillin levels in the cerebrospinal fluid during treatment of bacterial meningitis.

Authors:  L D Thrupp; J M Leedom; D Ivler; P F Wehrle; B Portnoy; A W Mathies
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965

6.  [Clinical experience with a new cephalosporin derivative, Cefotaxim].

Authors:  P M Shah; E B Helm; W Stille
Journal:  Med Welt       Date:  1979-02-23

7.  A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.

Authors:  G H McCracken; S G Mize
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

8.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

9.  Coliform meningitis in the newborn.

Authors:  J Z Heckmatt
Journal:  Arch Dis Child       Date:  1976-08       Impact factor: 3.791

10.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

View more
  6 in total

1.  Reverse inoculum effect in bactericidal activity and other variables affecting killing of group B streptococci by penicillin.

Authors:  L Jokipii; P Brander; A M Jokipii
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

Review 2.  A perspective on new beta-lactam antibiotics in pediatric patients.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 3.  Cephalosporins in gram-positive infections.

Authors:  J Symonds; A M Geddes
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Ceftriaxone (Ro 13-9904) therapy of serious infection.

Authors:  R W Bradsher
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

Review 6.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.